Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-681-1 | CAS number: 98-56-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
Evidence of carcinogenic activity via inhlation route
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- T25
- 738.45 mg/m³
- Study duration:
- chronic
- Species:
- rat
- System:
- other: hepatobiliar, respiratory tract
- Organ:
- alveoli
- bronchioles
- liver
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
According to the CLP Regulation n. 1272/2008, for the purpose of classification for carcinogenicity, substances are allocated to one of two categories based on the following criteria:
Category 1A: known to have carcinogenic potential for humans, classification is largely based on human evidence
Category 1B: presumed to have carcinogenic potential for humans, classification is largely based on animal evidence.
The classification in Category 1A and 1B is based on strength of evidence together with additional considerations (see section 3.6.2.2). Such evidence may be derived from:
— human studies that establish a causal relationship between human exposure to a substance and the development of cancer (known human carcinogen); or
— animal experiments for which there is sufficient evidence to demonstrate animal carcinogenicity (presumed human carcinogen).
In addition, on a case-by-case basis, scientific judgement may warrant a decision of presumed human carcinogenicity derived from studies showing limited evidence of carcinogenicity in humans together with limited evidence of carcinogenicity in experimental animals.
CATEGORY 2:
Suspected human carcinogens
The placing of a substance in Category 2 is done on the basis of evidence obtained from human and/or animal studies, but which is not sufficiently convincing to place the substance in Category 1A or 1B, based on strength of evidence together with additional considerations (see section 3.6.2.2). Such evidence may be derived either from limited evidence of carcinogenicity in human studies or from limited evidence of carcinogenicity in animal studies.
The test substance shows carcinogenic effects on several organs in the studies carried out on rats and mice. Only studies on rodents are however available, showing limited evidence in animals. No data on human is available.
For this reason, the substance is classified as Carc. 2 according to the CLP Reagulation n. 1272/2008.
Additional information
Two chronic studies are available on PCBTF, one on mice and the other one on rats.
In the study on rats, groups of 50 male and 50 female rats were exposed by whole body inhalation to p-chloro-α,α,α-trifluorotoluene at concentrations of 0, 100, 300, or 1,000 ppm for 6 hours plus T90 (12 minutes) per day, 5 days per week for 104 to 105 weeks. There was a significant negative trend in survival of males and survival of 1,000 ppm males was significantly less than that of the chamber controls; survival of other exposed groups of males and all exposed groups of females was similar to that of the chamber controls. Mean body weights of 100 and 300 ppm males and females were similar to those of the chamber controls throughout the study. The mean body weights of 1,000 ppm males were approximately 10% less than the chamber controls at the beginning of the study and subsequently were within 5% to 10% of the chamber controls for the remainder of the study. Female body weights in the 1,000 ppm group were within 10% of the chamber controls until week 72 and were approximately 10% less than the chamber controls for the remainder of the study.
In the thyroid gland, there were significantly increased incidences of C-cell adenoma in 1,000 ppm males and 100 and 1,000 ppm females.
There were occurrences of alveolar/bronchiolar adenoma and alveolar/bronchiolar carcinoma in the 100 and 1,000 ppm groups of male rats; these neoplasms were not observed in the chamber controls. There were significantly increased incidences of chronic inflammation of the lung in all exposed groups of males and females. There were significantly increased incidences of fibrosis of the lung in all exposed male groups and in 300 and 1,000 ppm females and of hemorrhage in all groups of exposed males and 1,000 ppm females.
In the adrenal medulla, there was a significantly increased incidence of benign pheochromocytoma in 1,000 ppm females, and the incidences of medullary hyperplasia were significantly increased in 300 and 1,000 ppm females.
In the uterus, there were positive trends in the incidences of adenocarcinoma and atypical hyperplasia of the endometrium and a significantly increased incidence of stromal polyp in 300 ppm females.
In the liver, there were significantly increased incidences of centrilobular hepatocyte hypertrophy in all exposed groups of males and in 300 and 1,000 ppm females and of fatty change in 300 and 1,000 ppm males and females. There were significantly increased incidences of eosinophilic focus in 1,000 ppm males and mixed cell focus and clear cell focus in 1,000 ppm females.
The severity of kidney nephropathy increased with increasing exposure concentration in male rats.
There was a significantly increased incidence of exudate in the nose of 1,000 ppm males.
In the study on mice, groups of 50 male and 50 female mice were exposed by whole body inhalation to p-chloro-α,α,α-trifluorotoluene at concentrations of 0, 100, 200, or 400 ppm for 6 hours plus T90 (12 minutes) per day, 5 days per week for 104 to 105 weeks. Survival of 400 ppm males was significantly less than that of the chamber controls; survival of 400 ppm females was similar to that of 400 ppm males, but was not significantly different from the chamber controls. Survival of other exposed groups of males and females was similar to that of the chamber controls. Mean body weights of exposed groups of males were similar to those of the chamber control group throughout the study. The mean body weights of 100 ppm females were at least 10% greater than those of the chamber control group generally after week 69. The mean body weights of 200 and 400 ppm females were at least 10% greater than those of the chamber controls after weeks 13 and 2, respectively. Clinical observations included increased occurrences of distended abdomen at removal. Thinness also occurred in 400 ppm males and females.
In the liver of 200 and 400 ppm groups, there were significantly increased incidences of multiple hepatocellular adenoma in males and hepatocellular adenoma (including multiples) in females. There were significantly increased incidences of hepatocellular carcinoma in all exposed groups of males and in 400 ppm females. There were significantly increased incidences of hepatoblastoma in 400 ppm males and females. There were significantly increased incidences of eosinophilic focus in 400 ppm males and in 200 and 400 ppm females. There were significantly increased incidences of centrilobular hepatocyte hypertrophy in all exposed groups of males and in 200 and 400 ppm females. There were significantly increased incidences of multinucleated hepatocytes in 200 and 400 ppm males and in 400 ppm females. The incidences of hepatocyte necrosis were significantly increased in 400 ppm males and females. There were also significantly increased incidences of intrahepatocellular erythrocytes in 200 and 400 ppm males.
In the Harderian gland, there was a significantly increased incidence of adenoma in 400 ppm females, and significantly increased incidences of adenoma or adenocarcinoma (combined) in 200 and 400 ppm females.
There were significantly increased incidences of alveolar/bronchiolar epithelium hyperplasia and peribronchiolar fibrosis of the lungs in all exposed groups of males and females.
There was a significantly increased incidence of epithelium hyperplasia in the forestomach of 400 ppm females. In males, there were significantly increased incidences of inflammation in the 100 and 400 ppm groups.
In the larynx, there was a significantly increased incidence of squamous epithelium hyperplasia in 400 ppm males.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.